Peptides in Wound Care: What FDA's 503A Review Means — and What's Landing in Your Inbox

It arrived on a Wednesday, addressed by name.

The sender had done his homework. He knew we work with hospitals and physician practices to build and manage outpatient wound care and hyperbaric medicine programs. He was friendly and brief and had a proposal: physician-use peptides, third-party tested, a natural extension of the services we already offer. A way for our partners to broaden regenerative options for their patients. A new revenue stream, he wrote, without a heavy lift on the operational side.

Three emails, just like that one, arrived in the same week. Different senders. Different companies. The same promise.

The easy version of this blog post is the wrong one. The easy version says, "Watch out!" It points at the gray market, lets everyone feel briefly superior, and sends them back to work none the wiser. That kind of blog post? Would be useless to you. That would also be wrong. Peptide drugs aren't new. Physicians have prescribed peptide medicines for more than a century. Insulin is a peptide. So are the GLP-1 medications that reshaped diabetes care. There is real peptide science in wound healing, and some of it in Phase III trials right now.

So, this post isn't a warning. It's a translation.

Because emails like these are written in language that sounds adjacent to medicine, function like marketing, and overlap just enough to be genuinely confusing.

If one of these emails landed in your inbox too, here's how to read it.

The Anatomy of a Peptide Sales Pitch

None of these emails’ strongest claims are actually claims. They're cues.

Each phrase nudges the reader toward a conclusion without ever quite saying it outright. Read together, they follow a familiar sequence: establish credibility, sound medical, borrow clinical authority, then make the business case.

Here's what each one is really doing.

"Third-party tested."

This is the language supplements use to establish trust. It signals that an outside laboratory examined a product, but it isn't the credential pharmaceutical manufacturers typically lead with. A registered outsourcing facility, the kind of pharmacy that supplies office stock to physician practices and hospitals, is far more likely to emphasize FDA registration and compliance with current good manufacturing practice (cGMP). Those? Are pharmaceutical credentials.

When the first credential comes from the adjacent, less regulated industry instead, that substitution itself is information.

It's also thinner than it sounds.

An endocrinologist at Weill Cornell said it plainly in July 2026, “…we don’t exactly know about the accuracy of the third-party testing.”¹ And the FDA's own review documents reach a similar conclusion. Publicly available certificates of analysis often report appearance, identity, and purity, but frequently omit assay, impurity profiles, protein aggregates, and bacterial endotoxin testing.²

"Physician-use peptides."

Sounds like a regulatory category, right? It isn’t.

There is no FDA regulatory category, designation, statutory definition, or recognized list. It's a marketing phrase that sits comfortably close to "prescription only" without ever claiming it.

That becomes easier to recognize when you notice how many of the very same compounds are sold elsewhere online under a very different label: Research Use Only. Not for Human Consumption.

"Regenerative options."

Which is a phrase that borrows credibility from an established field.

Regenerative medicine is indeed real. Cellular and tissue-based products (CTPs) are regenerative. Autologous grafts (Autografts) are regenerative. Platelet-rich plasma (PRP) is regenerative, and Medicare's National Coverage Determination defines exactly when it may be covered, for whom, and for how long.³

Those therapies earned their place through clinical trials, FDA review, payer policies, and coding guidance.

Using the same vocabulary for an entirely different category of products quietly imports credibility that was built somewhere else.

"A new revenue stream without a heavy lift on the operational side."

Anyone who has ever worked inside an outpatient wound care department knows everything legitimate has a heavy lift.

Medical necessity narratives.

National Coverage Determinations (NCDs).

Local Coverage Determinations (LCDs).

Local Coverage Articles (LCAs).

Prior authorizations.

Conservative care documented across weeks before an advanced therapy is even considered.

None of that is unnecessary bureaucracy attached to covered care. That work is what creates a reimbursable medical claim.

So when an opportunity promises "no heavy lift," it is telling you something genuine.

There's no documentation burden because there's no medical necessity narrative, because there's no prior authorization, because there's no claim. Cash, at the point of service, in a department that bills Medicare for everything else it does.

In an outpatient wound program, "no heavy lift" isn't a selling point. It's a finding.

Why Peptide Emails Started Showing Up in Inboxes

These emails are not a coincidence. They arrived at the end of a sequence of events that had been building since spring of 2026.

In April 2026, FDA removed a group of peptides from what's called Category 2 — a designation for bulk substances the agency had flagged as potentially presenting significant safety risks. Coming off that list lowered a barrier. It did not create permission. Nothing about the removal made these compounds legal to compound; it simply cleared the way for the question to be formally asked.⁴

That question got scheduled almost immediately. On April 16, 2026, a Federal Register notice announced a two-day advisory committee meeting for July 23 and 24, and opened a public docket for comment.⁵

Marketing teams tracked the calendar perfectly. In the week before the advisory committee met, peptide messaging seemingly appeared everywhere at once. A consumer survey surfaced in local television markets across the country on the very same day. That kind of synchronicity rarely happens organically and usually reflects a coordinated media campaign rather than dozens of independent newsrooms deciding the same story matters simultaneously. The survey was produced by a company that sells peptide-related services. Its central finding was that people already familiar with peptides would like easier access to peptides.

Then, on Thursday, July 23, 2026, the committee voted.

Four compounds received favorable recommendations for the 503A Bulks List: BPC-157, KPV, TB-500, and MOTS-c. Two, KPV and TB-500, were evaluated specifically for wound healing.⁵ ⁶

And the committee reached that recommendation over the objection of FDA's own scientific reviewers, who had published briefing documents in advance proposing that none of these substances be added.⁷

Two things about that vote matter enormously and rarely make headlines.

It is not binding. The Pharmacy Compounding Advisory Committee advises. FDA decides. The agency usually follows its advisory committees, but it is not required to.⁶

And it is not a finish line. A favorable recommendation is the beginning of a regulatory process, not the end of one.

So: a barrier came down in April, a meeting was scheduled, the docket filled up, marketing accelerated, and a divided committee voted yes against its own agency's scientists. That’s why your inbox looks different today than it did three months ago.

Everything laid out so far explains why four phrases keep showing up in peptide sales pitches. The committee vote adds a fifth, and it's stronger than all the others because this time the statement is factually correct:

An FDA advisory committee voted in favor. And that's precisely where the confusion begins.

Compoundable Is Not Approved

Four labels get attached to these compounds, and to most readers they look like rungs on a ladder: FDA-approved at the top, then on the 503A Bulks List, then compounded by a registered outsourcing facility, then research use only at the bottom.

They aren't rungs. They're four different legal objects governed by four different rulebooks, and the confusion between them is the surface every one of these pitches is built on.

Federal law is clear about the structure. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a bulk drug substance may be used in patient-specific compounding only if it clears one of three gates: it complies with an applicable United States Pharmacopeia monograph; or, if no monograph exists, it is a component of an FDA-approved drug; or, if neither applies, it appears on the 503A Bulks List.⁵

That third gate is what the advisory committee met to consider.

And here is the part almost nobody explains, because you have to see it written down to believe it.

Section 503A is not an approval pathway. It's an exemption.

Specifically, it exempts qualifying compounded drugs from three requirements of federal drug law: current good manufacturing practice standards, labeling with adequate directions for use, and new drug approval.⁵

Read that again with a wound program's eyes. A substance reaching the 503A Bulks List does not mean FDA reviewed it and found it safe and effective. It means the compounded preparation is excused from the manufacturing standards, the labeling requirements, and the approval process that every drug on your formulary had to satisfy.

That distinction was raised inside the room, during the vote, by a member of the committee. Brian Lee, MD, associate professor of medicine at the Keck School of Medicine of USC, warned that while the vote would not constitute FDA approval, consumers would nonetheless perceive it as an endorsement.⁷

The endocrinologist quoted earlier made the same point from the exam room: reclassification lets a physician write a prescription, but it doesn't make the substance FDA-approved, and it doesn't generate a single new data point about safety or efficacy.¹

And there is one more gate past all of them — one wound care knows better than most specialties.

Becaplermin, sold as Regranex, is a recombinant human platelet-derived growth factor. It cleared the entire approval gauntlet. It is an FDA-approved drug for diabetic foot ulcers. And Medicare's national coverage determination lists it as nationally non-covered for chronic, non-healing subcutaneous wounds.³

CMS stated both facts in the same breath. When the agency corrected that section of its manual in 2006, the correction notice reads, in part: becaplermin is approved by the Food and Drug Administration, and coverage will remain nationally non-covered.³

Approved is not covered. Compoundable is not approved. And none of the three is a clinical outcome.

When a Name Doesn't Identify a Molecule

The most surprising moment in the entire advisory committee meeting wasn't the vote. It was the moment FDA explained that it can't always say exactly what these compounds are.

Russell Wesdyk, an FDA scientist, described it as a foundational challenge. Compounds sold under the same name don't always share the same chemistry. "You will see many, many different forms," he told the committee. "We can't create quality standards until we actually know what it is."⁷

Another FDA staffer illustrated the problem using BPC-157. The agency had encountered multiple substances all marketed as "BPC-157" that turned out to contain different active molecules. The FDA staffer explained that there is no basis for expecting that a common name will reliably identify the same substance — the same specific chemical form and structure — from one supplier to the next.⁷

The name on the vial, by itself, isn't a chemical specification. Two products may both be labeled "BPC-157," come from different suppliers, and still not represent the same chemical substance. If that's true, ordering by name alone doesn't necessarily guarantee that every supplier is providing the same molecule.

That's not simply a manufacturing problem. It's a scientific one.

How do you establish quality standards for a substance if you can't first establish exactly what substance everyone is talking about?

That identity problem wasn't an isolated concern raised during the meeting. It appears throughout FDA's briefing documents and became one of the reasons the agency's scientific reviewers recommended against adding these compounds to the 503A Bulks List. Across multiple reviews, FDA staff reached the same conclusion: the available evidence was insufficient to establish safety and effectiveness for the proposed uses, and much of the supporting literature consisted of animal studies rather than human clinical trials.⁶

And then the committee voted to recommend them anyway.⁷

An FDA advisory committee recommended these substances for compounding.

FDA scientists who evaluated them recommended the opposite.

Both statements are now true at the same time.

One recommendation will almost certainly appear in future marketing emails.

The other is buried inside hundreds of pages of FDA briefing documents.

That is worth stating plainly, because the vote is what the sales emails will cite, and the vote is the part most easily misread.

The agency cannot yet define, with confidence, what "these substances" even are. That gap isn't abstract. It's clinical.

The Paper Trail of a Single Peptide

Take one of the two peptides the FDA evaluated specifically for wound healing and follow its file. Not the marketing. The file.

The peptide? TB-500.

In the wellness world, it's often described as a synthetic version of thymosin β4, a naturally occurring protein with a decades-long history of wound-healing research. That description is where the story begins to change.

TB-500 is not thymosin β4.

Thymosin β4 is a naturally occurring protein made up of 43-amino acids. TB-500 is a synthetic fragment consisting of 7-amino acids. FDA's own briefing document states this directly and notes that the two names are frequently used interchangeably online even though they are not the same substance.²

That distinction is not academic.

When the nomination to place TB-500 on the 503A Bulks List was submitted, it cited three scientific references as supporting evidence. FDA reviewed those citations and found that all three studied thymosin β4, not TB-500.²

The evidence offered for the seven-amino-acid fragment had been borrowed from the forty-three-amino-acid protein.

So, the FDA went looking for evidence on TB-500 itself.

The agency's first question was simple: Has this compound ever been studied for human use?

The answer? "After conducting a literature search, no articles were found in which TB-500 was administered to humans."² Not preliminary, limited, or thin. None.

The next question was equally straightforward: Does TB-500 actually promote wound healing?

In the one laboratory study the FDA identified, TB-500 in its nominated free-base form appeared, in the agency's words, "devoid of wound-healing properties," showing no statistically significant difference from the control. A breakdown product of the molecule produced a small effect; the nominated compound itself did not. The FDA concluded that it remains unknown whether either form improves wound healing in a living body at all.²

Then FDA looked for safety data.

The agency found no acute toxicity studies, repeat-dose studies, genotoxicity studies, carcinogenicity studies, or reproductive or developmental toxicity studies.²

For a molecule promoted in wound healing because of its effects on angiogenesis, the absence of carcinogenicity data isn't a footnote. It's a question clinicians would, reasonably, want answered.

Then the FDA noticed something that will make every compliance officer cringe.

The nomination could not consistently say what molecule it was nominating.

According to FDA's review, the application nominated one chemical form while attaching a certificate of analysis for another. Registry numbers corresponded to different substances. Molecular formulas conflicted with both. The agency summarized the problem plainly: the identity of the nominated substance was unclear.²

The nomination was later withdrawn.²

One final question remained: Where had TB-500 even come from?

FDA's review traces an unusual path. The peptide was synthesized from thymosin β4 in 2003. It later appeared in veterinary products marketed for racehorses and racing greyhounds and is on the World Anti-Doping Agency's prohibited list.²

So, TB-500’s documented path runs from the animal track, through athletic doping, into wellness clinics, and, in July 2026, into a wound care company's inbox.

None of those facts are hidden. Every fact above is in an FDA document, published and made freely available to the public and to the committee.

Although, none of those facts, by themselves, answer whether TB-500 should, or should not, be compounded.

They do, however, explain why FDA's scientific reviewers reached the recommendation they did. And they also explain why reading the receipts matters more than reading marketing copy.

That is the gap this blog post is about. Not a gap between good peptides and bad ones — a gap between what a name promises and what a file contains. The name said wound healing. The file said no human data, no toxicology, no stable identity, and a trip through the veterinary performance-enhancing drug (PED) market. Reading the difference is the entire skill.

What's Actually Real in Peptide Wound Care

This blog post, so far, has been about one email and one committee vote and if it ended here, it would be easy to continue surfing with the wrong conclusion.

That conclusion? That peptides have no place in wound care.

The evidence says something much more interesting.

There is a real, active, published field of peptide research in wound healing. Scientists have spent decades studying peptides that mimic the body's own repair signals, and several are moving through the same development pathway expected of any serious therapeutic.

One, a connexin-based peptide called αCT1, has reached Phase III trials in diabetic foot ulcers.⁸ Another, the antimicrobial peptide LL-37, has been tested in a randomized, placebo-controlled trial for hard-to-heal venous leg ulcers.⁸ Also, peptide-based wound dressings and hydrogel delivery systems are already on the market. The science is real, and some of it is genuinely promising.

Now compare those peptides (αCT1 and LL-37) with the ones that were considered at the July 2026 FDA advisory committee meeting (BPC-157, KPV, TB-500, MOTS-c).

The peptides carrying the actual clinical evidence in wound care are, almost entirely, not the ones the committee voted on at that meeting.

One group is progressing through the traditional pathway of laboratory research, human clinical trials, regulatory review, and, eventually, potential approval. The other entered this discussion through a compounding pathway built around a different set of legal questions.

That distinction matters.

The clearest example is the one peptide with the strongest wound-healing and collagen literature of all: GHK-Cu, a naturally occurring copper-binding peptide.

Notably, GHK-Cu wasn't even on the July 2026 agenda.

It's scheduled for a second advisory committee meeting, expected before the end of February 2027.⁹ In the meantime, topical GHK-Cu remains in FDA's "under evaluation" category, meaning the agency is continuing its review while declining, for now, to act against pharmacies that compound it.⁴ ⁹ Which is a more cautious regulatory posture than the one surrounding the several peptides that generated headlines in July 2026.

That is worth pausing on, because it points the opposite direction from the sales emails. The peptides arriving in inboxes with "voted in favor" headlines are not, for the most part, the ones carrying the strongest clinical evidence in wound care.

Fair warning: "Under evaluation" is not an approval, endorsement, or finding of safety or effectiveness. It is simply another regulatory status and happens to sound more definitive than it actually is.

So the honest answer to "should our wound program get into peptides?" isn't yes, and it isn't no. It's three smaller questions: which peptide, through which regulatory pathway, and supported by what evidence?

Peptides are already part of wound care's future. They are simply not, for the most part, the ones currently being sold to you — and not through the door currently being propped open.

What a "Yes" Vote Actually Sets in Motion

The single most important thing to understand about the July 2026 vote is what it did not do.

It did not make these peptides legal to compound. It did not approve them. It did not change what a pharmacy may compound. A favorable recommendation from an advisory committee is a signal, not a switch.

So, here's what actually happens next.

Step one: the advisory committee makes a recommendation. That's what happened on July 23, 2026. That recommendation is advisory and non-binding. The FDA is free to accept it, modify it, or reject it altogether. The agency usually follows its advisory committees, but it is not required to, and the recommendation carries no legal force on its own.⁶

Step two: if the FDA agrees a peptide should be added to the 503A Bulks List, it cannot simply announce it. It has to go through the formal notice-and-comment rulemaking process. That means publishing a proposed rule, accepting public comments, reviewing those comments, and ultimately issuing a final rule.

Step three: only after that process is complete would a substance become eligible for lawful compounding under Section 503A.

That's why the current status is easy to misunderstand. So where does that leave things today? An advisory committee has recommended adding four peptides to the 503A Bulks List.

No proposed rule has been issued. No public comment period has opened. And even if every remaining step proceeds smoothly, the regulatory process is generally measured in months to years, not days.¹⁰

The FDA has not made a decision — which is worth keeping in mind when any incoming peptide marketing emails hit your inbox.

If an email says an FDA advisory committee voted in favor, that’s true.

If it leaves the recipient with the impression that the FDA has already approved these peptides for routine compounding… that’s a very different claim.

What This Means Monday Morning

Strip away the committee vote, the Federal Register notices, and the regulatory vocabulary, and here is what actually arrives on a Monday morning: a patient, in a podiatry chair, who has already started taking peptides.

An endocrinologist at Weill Cornell described seeing roughly a dozen patients in a single month who raised peptides with her directly — not because a physician suggested them, but because they'd already found them.¹ That's the real front line. Not the inbox. The exam room. By the time the sales email reaches your clinic manager, some of your patients have been ordering these compounds online for months, from sources with a "not for human consumption" label on the vial.

So the useful question was never "should we sell peptides?" It's "what do we say when a patient asks?"

A few things worth having ready before that conversation happens.

Know the four categories cold. FDA-approved, on the 503A Bulks List, compounded by a registered outsourcing facility, and "research use only." They are not a ladder, and a patient — or a vendor — using one term may mean another. Precision here is patient safety, not pedantry.

Read the file, not the headline. "An FDA advisory committee voted in favor" is true and nearly meaningless on its own. The question underneath it is always the same: approved, or compoundable, or neither — and backed by what evidence, in humans, for this use?

Remember the layer below federal. Even if a substance clears the entire 503A process, state boards of pharmacy hold their own authority, and several states regulate compounding more strictly than the federal framework requires.⁴ Where you practice matters as much as what FDA decides.

Separate compoundable from approved, and approved from covered.

None of that requires a wound program to take a position on whether peptides are the future of regenerative medicine. It requires the program to read carefully, document honestly, and answer a nervous patient with something more useful than a brochure.

SHS Insight: The programs that navigate moments like this best aren't the ones with the fastest answers. They're the ones that prepared for the questions before patients started asking them.

The SHS Difference

For more than 30 years, Shared Health Services has helped hospitals and physician practices navigate exactly these kinds of moments. New therapies. New regulations. New reimbursement questions. Our work isn't simply helping programs respond after the headlines arrive. It's building the documentation, education, and compliance systems that let teams respond confidently before they do.

When a headline outpaces the evidence, the difference between a program that reacts and a program that's ready is the work done before the email arrives.

To talk through what this looks like for your program, reach us at (800) 474-0202 or sales@sharedhealthservices.com.

References:

1. Howard B. 10 questions to ask your doctor about peptides. Association of American Medical Colleges. Published July 21, 2026. Accessed July 28, 2026. https://www.aamc.org/news/10-questions-ask-your-doctor-about-peptides

   
   

2. US Food and Drug Administration. FDA briefing document: TB-500-related bulk drug substances (TB-500 (free base) and TB-500 acetate). Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. Published May 15, 2026. Accessed July 28, 2026. https://www.fda.gov/media/193349/download

   
   

3. Centers for Medicare & Medicaid Services. National coverage determination (NCD) for blood-derived products for chronic non-healing wounds (270.3). Version 6. Effective April 13, 2021. Medicare Coverage Database. Accessed July 28, 2026. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=217

   
   

4. Liebman SS, DiSabatino DP, Inman C, Mercer A. What to watch: status update on peptide regulation. Sheppard Mullin FDA Law Update. Published June 15, 2026. Accessed July 28, 2026. https://www.sheppard.com/insights/blogs/what-to-watch-status-update-on-peptide-regulation

   
   

5. Pharmacy compounding advisory committee; notice of meeting; establishment of a public docket; request for comments—bulk drug substances nominated for inclusion on the section 503A bulk drug substances list. Fed Regist. 2026;91:20465-20467. Docket No. FDA-2025-N-6895. Published April 16, 2026. Accessed July 28, 2026. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request

   
   

6. Stone W. FDA panel backs easier access to peptides. NPR. Published July 23, 2026. Updated July 23, 2026. Accessed July 28, 2026. https://www.npr.org/2026/07/23/nx-s1-5903202/fda-peptides-restrictions

   
   

7. Choi J. FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists. The Hill. Published July 23, 2026. Accessed July 28, 2026. https://thehill.com/homenews/5987510-fda-committee-votes-peptides/

   
   

8. Kamil RM, Nyamathulla S, Mahmood S. Peptides in wound healing: a comprehensive review of their roles, challenges, and hydrogel-based delivery systems. EXCLI J. 2025;24:1657-1689. doi:10.17179/excli2025-8778

   
   

9. US Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026. Accessed July 28, 2026. https://www.fda.gov/media/94155/download

   
   

10. Jeffries E. FDA panel recommends easing restrictions on 4 peptides: what to know. Becker's Hospital Review. Published July 23, 2026. Updated July 24, 2026. Accessed July 28, 2026. https://www.beckershospitalreview.com/glp-1s/fda-to-vote-on-peptide-compounding-what-to-know/